Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Dongguk University Industry-Academic Cooperation Foundation is managing 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 4 distinct examiners across 3 distinct art units. This distribution indicates that multiple examiners are likely operating within the same specialized group, which may lead to some consistency in procedural expectations.
MCKOY, QUINCY ANDRE is the busiest examiner for the portfolio. This examiner is responsible for 1 pending office action. Since there are 4 distinct examiners for the 4 pending office actions, the workload is evenly distributed. This lack of examiner-level consolidation requires the university to manage four separate examiner relationships simultaneously.
The presence of 3 distinct art units for 4 pending office actions suggests a focused technical scope within the Biotechnology & Pharmaceuticals sector. However, the use of 4 distinct examiners means that practitioners must still account for individual variations in examination style. The 1 pending office action assigned to MCKOY, QUINCY ANDRE represents the typical workload per examiner for the university's current applications.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| §112 only | 2 (50%) |
| Double-patenting + other | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCKOY, QUINCY ANDRE | 1 | 68.8% | +39.4% |
| FIEBIG, RUSSELL G | 1 | 62.6% | +25.0% |
| GIBBS, TERRA C | 1 | 63.7% | +10.3% |
| WILSON, MICHAEL C | 1 | 41.5% | +17.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18707936 | COMPOSITION FOR CURING HANGOVER OR IMPROVING LIVER FUNCTION, COMPRISING PINE HEARTWOOD EXTRACT AS ACTIVE INGREDIENT | FIEBIG, RUSSELL G | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18270915 | METHOD FOR DIAGNOSIS AND TREATMENT OF AUTISM SPECTRUM DISORDER ON BASIS OF ACTIVITY REGULATION MECHANISM OF DORMANT NEURAL STEM CELL | GIBBS, TERRA C | 20d |
| 18723672 | NOVEL LEUKOTRIENE B4 RECEPTOR INHIBITORS AND USE THEREOF | MCKOY, QUINCY ANDRE | — |
| 18707936 | COMPOSITION FOR CURING HANGOVER OR IMPROVING LIVER FUNCTION, COMPRISING PINE HEARTWOOD EXTRACT AS ACTIVE INGREDIENT | FIEBIG, RUSSELL G | — |
| 18041125 | NOVEL METHOD FOR PREPARING ANIMAL MODEL OF CEREBROVASCULAR DISEASE AND METHOD FOR PRODUCING ANIMAL HAVING SMALL INDIVIDUAL DIFFERENCE IN SUSCEPTIBILITY TO CEREBROVASCULAR DISEASE ONSET BY USING ANIMAL MODEL FOR CEREBROVASCULAR DISEASE PREPARED THEREBY | WILSON, MICHAEL C | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| 1635 | 1 |
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18723672 | NOVEL LEUKOTRIENE B4 RECEPTOR INHIBITORS AND USE THEREOF | MCKOY, QUINCY ANDRE | — | §102DP | Non-Final OA | — | Pending | Jun 24, 2024 |
| 18707936 | COMPOSITION FOR CURING HANGOVER OR IMPROVING LIVER FUNCTION, COMPRISING PINE HEARTWOOD EXTRACT AS ACTIVE INGREDIENT | FIEBIG, RUSSELL G | 1655 | §101§103§112 | Final Rejection | — | Pending | May 07, 2024 |
| 18270915 | METHOD FOR DIAGNOSIS AND TREATMENT OF AUTISM SPECTRUM DISORDER ON BASIS OF ACTIVITY REGULATION MECHANISM OF DORMANT NEURAL STEM CELL | GIBBS, TERRA C | 1635 | §112 | Final Rejection | 20d | Pending | Jul 05, 2023 |
| 18041125 | NOVEL METHOD FOR PREPARING ANIMAL MODEL OF CEREBROVASCULAR DISEASE AND METHOD FOR PRODUCING ANIMAL HAVING SMALL INDIVIDUAL DIFFERENCE IN SUSCEPTIBILITY TO CEREBROVASCULAR DISEASE ONSET BY USING ANIMAL MODEL FOR CEREBROVASCULAR DISEASE PREPARED THEREBY | WILSON, MICHAEL C | 1638 | §112Other | Non-Final OA | — | Pending | Apr 05, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial